Boknik, P. et al. 2000. Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn Schmiedebergs Arch Pharmacol. 362(3), pp.222-31.
Boknik, P. et al. 2001. Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovascular Research. 51(4), pp.717-728.
Bye, A. et al. 2008. Carbon monoxide levels experienced by heavy smokers impair aerobic capacity and cardiac contractility and induce pathological hypertrophy. Inhalation Toxicology. 20(7), pp.635-646.
Chakraborty, A. et al. 2014. Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor. PLoS One. 9(8), pe104338.
Chen, X.W. et al. 2011. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology. 50(3), pp.460-470.
Denipote, F. et al. 2011. Influence of Taurine on Cardiac Remodeling Induced by Tobacco Smoke Exposure. Cellular Physiology and Biochemistry. 27(3-4), pp.291-298.
Guinto, P.J. et al. 2009. Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol. 297(2), pp.H614-26.
Song, L.S. et al. 2005. Paradoxical cellular Ca2+ signaling in severe but compensated canine left ventricular hypertrophy. Circulation Research. 97(5), pp.457-464.
Badrilla is a manufacturer of outstanding antibodies against cardiac proteins and phospho-proteins, and the manufacturer of leading kits for the study of protein S-palmitoylation.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.